- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06910813
DFT383 hos pediatriske deltakere med nefropatisk cystinose (CYStem)
En åpen, multisenter, fase I/II-studie for å vurdere sikkerhet, toleranse og effekt av DFT383 hos pediatriske deltakere med nefropatisk cystinose
An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.
The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.
This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.
Studieoversikt
Detaljert beskrivelse
This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.
The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.
Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.
The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.
Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.
Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-post: novartis.email@novartis.com
Studer Kontakt Backup
- Navn: Novartis Pharmaceuticals
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85016
- Rekruttering
- Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
-
Ta kontakt med:
- Erica Sieber
- Telefonnummer: 602-933-0171
- E-post: esieber@phoenixchildrens.com
-
Hovedetterforsker:
- Shanna White
-
-
California
-
San Diego, California, Forente stater, 92123
- Rekruttering
- University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
-
Ta kontakt med:
- Mieko Pretlow
- Telefonnummer: Ext 226010 858-966-1700
- E-post: mpretlow@rchsd.org
-
Hovedetterforsker:
- Nadine Benador nbenador@health.ucsd.edu
-
Stanford, California, Forente stater, 94305
- Rekruttering
- Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
-
Hovedetterforsker:
- Alice Bertaina
-
Ta kontakt med:
- Research Nurse
- Telefonnummer: (650) 725-9032
- E-post: scgt_clinical_trials_office@lists.stanford.edu
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
-
Hovedetterforsker:
- Laurence (Larry) Greenbaum
-
Ta kontakt med:
- Laurence (Larry) Greenbaum
- Telefonnummer: 404-712-6374
- E-post: lgreen6@emory.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia (Recruiting Cohort 0)
-
Ta kontakt med:
- Melissa Cadnapaphornchai
- Telefonnummer: 215-590-2449
-
Hovedetterforsker:
- Melissa Cadnapaphornchai
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
-
Ta kontakt med:
- Ewa Elenberg
- Telefonnummer: 832-824-3800
- E-post: Email_elenberg@bcm.edu
-
Hovedetterforsker:
- Ewa Elenberg
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
Participants eligible for inclusion in this study must meet all the following criteria:
- Informed consent in writing from parent(s) or legal guardian(s) must be provided
- 2 to 5 years of age (including 5 years and 364 days old) at Screening
- Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
- Oral cysteamine therapy for at least 6 months
- Historic clinical diagnosis of nephropathic cystinosis
- Laboratory evidence of of renal fanconi syndrome (RFS)
- Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
- Received all age-appropriate vaccinations
Key exclusion Criteria for Cohort 1 and 0
- A history of kidney transplantation
- A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
- History of malignancy
- A severe or uncontrolled medical disorder
- Major surgery within 90 days
Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:
1. Indomethacin within 2 weeks prior to Screening
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort 1 (DFT383)
Treatment with DFT383 |
DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy. |
|
Ingen inngripen: Cohort 0 (SoC)
No study treatment, will continue with standard of care (cysteamine). |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Core Phase - Incidence of adverse events (Cohort 1)
Tidsramme: Up to 32 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 32 months
|
|
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Tidsramme: 42 days post DFT infusion
|
Hematological reconstitution by Day 42 post-DFT383 infusion |
42 days post DFT infusion
|
|
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Tidsramme: Up to 32 months
|
Proportion of participants with reversal of renal Fanconi syndrome (RFS) |
Up to 32 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Core Phase - Number of participants independent from cysteamine
Tidsramme: up to 24 months
|
Independence from oral and ophthalmic cysteamine |
up to 24 months
|
|
Core Phase - Health-related quality of life (HRQOL)
Tidsramme: Up to 32 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 32 months
|
|
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Tidsramme: Up to 24 months
|
Time from infusion to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Tidsramme: Up to 24 months
|
Time from screening to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Duration of reversal of RFS
Tidsramme: Up to 24 months
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Tidsramme: Up to 27 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 27 months
|
|
Core Phase - Change from baseline on urine amino acids
Tidsramme: Up to 27 months
|
Change from baseline on urine amino acids |
Up to 27 months
|
|
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Tidsramme: Up to 27 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Tidsramme: Up to 27 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Tidsramme: Up to 27 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 27 months
|
|
Core Phase - Number of participants with improvement of proximal tubular function
Tidsramme: Up to 27 months
|
Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization. |
Up to 27 months
|
|
Core Phase - Corneal cystine crystal content
Tidsramme: Up to 27 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 27 months
|
|
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Tidsramme: Up to 27 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 27 months
|
|
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Tidsramme: Up to 27 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 27 months
|
|
Core Phase - Number of participants with malignancy (Cohort 1)
Tidsramme: Up to 27 months
|
Number of participants with malignancy |
Up to 27 months
|
|
Core Phase - Time to hematological reconstitution (Cohort 1)
Tidsramme: Up to 24 months
|
Time to hematological reconstitution |
Up to 24 months
|
|
Core Phase - Time to platelet engraftment (Cohort 1)
Tidsramme: Up to 24 months
|
Time to platelet engraftment |
Up to 24 months
|
|
Core Phase - Incidence of Adverse Events (Cohort 0)
Tidsramme: up to 24 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
up to 24 months
|
|
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Tidsramme: Up to 15 years and 8 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 15 years and 8 months
|
|
Extension Phase - Number of participants with malignancy (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Number of participants with malignancy |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Change from baseline on urine amino acids |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Duration of reversal of RFS (Cohort 1)
Tidsramme: Up to 15 years
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 15 years
|
|
Extension Phase - Number of participants with kidney failure (Cohort 1)
Tidsramme: Up to 15 years
|
Number of participants with kidney failure |
Up to 15 years
|
|
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Tidsramme: Up to 15 years
|
Independence from oral and ophthalmic cysteamine |
Up to 15 years
|
|
Extension Phase - Corneal cystine crystal content (Cohort 1)
Tidsramme: Up to 15 years and 3 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 15 years and 3 months
|
|
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Tidsramme: Up to 15 years and 8 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 15 years and 8 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Renal tubulær transport, medfødte feil
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Ernæringsmessige og metabolske sykdommer
- Cystinose
- Fanconi syndrom
- Lysosomale lagringssykdommer
Andre studie-ID-numre
- CDFT383A12101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .